ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2024 World Conference on ...

NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people. Looking back over the journey from our humble beginnings ...

Peers & Perspectives in Oncology: Could you explain the recent indirect analysis of lurbinectedin (Zepzelca) vs topotecan in pretreated patients with ES-SCLC who have a chemotherapy-free interval ...